Search PubMed⌕ Search

Biomedical subjects

S Wiersbitzky

Publications and source records attributed to S Wiersbitzky.

At least 73 records · Page 4Linked to original sources
PubMed1991

The eosinophilic granulocyte count in the respiratory secretions of children with chronic nonspecific respiratory diseases.

We performed cytologic evaluations of 6116 nasal and/or bronchial smears from 4510 patients (average age: 7.6 years; 3 months--17 years) suffering from different kinds of chronic nonspecific respiratory diseases (CNSRD); in 137 children (average age: 4.8 years) undergoing bronchologic examinations under general anesthesia we compared the findings with those for bronchoalveolar lavage (BAL). Nasal smears of 77 healthy children at a day care center (control group) were analysed four times per year for "significant secretory eosinophilia" (SEE; i.e. more than 13% eosinophils). We found: 1. Healthy children do not have such "SSE" in contrast to children with CNSRD who show different frequencies of "SSE" depending on the age of the child and the specific kind (diagnosis) of CNSRD. 2. 4.6% of infants (first year of life) were found to have SSE with a statistically significant correlation to increase in the following 10 years up to 50% of all children (p less than 0.001). 3. We found SSE in 4.41% of cases with relapsing bronchitis, in 7.14% (8.3% resp.) with chronic bronchitis, in 6.49% (9.2% resp.) with relapsing or chronic obstructive bronchitis and in 46.05% (55.3% resp.) with bronchial asthma (p less than 0.001). 4. The intensity of obstructive symptoms (nose: rhinitis; bronchus: dyspnoea) did not correlate with the number of eosinophils in the secretions. 5. Only the smear cytograms (nose/bronchus) enabled us to detect "SSE" whereas BAL cytograms were too insensitive (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1991

[Diagnostic value of skin tests in children with bronchial asthma and/or atopic eczema].

Positive test results with relevance to the patients' history resp. illness' development were seen in all age groups of patients suffering from asthma. In cases with atopic dermatitis, but without asthma or bronchitis, positive test reactions were not relevant; in these cases hyperreagibility of the skin is supposed. The results confirmed that cutaneous testing is indicated in children suffering from asthma, even in those cases with associated atopic dermatitis provided that testing is carried out in lesion-free skin-area and beyond exacerbation of eczema. Test-results should be interpreted only with regard to the patients' history, clinical picture and its development.

Adolescent↗
PubMed1990

[Parvovirus B19 infections in Germany 1987-1988].

3289 sera of patients were tested for Parvovirus B19 specific antibodies (IgM/IgG) by ELISA for routine virological diagnostics in 1987/1988. Acute B19 infection could be confirmed in 14.5%, while 24.4% were already immune and in 61.1% antibodies could not be detected. Only 0.12% of all sera were B19-DNA positive by nucleic acid hybridisation. The highest rate of acute B19 infections could be detected in the age-group of the 6-15 year old. Infections occurred above all in the period of January to July resp. August. The most frequent clinical manifestation of acute B19 infection was exanthema (54.4%) and arthritis/arthralgia (6.5%).

Adolescent↗
PubMed1990

[Seroprevalence of human parvovirus B 19 antibodies (Sticker's disease/erythema infectiosum) in the DRG population].

We tested 638 human sera of all age groups (patients and blood donors) from the northern area of the G.D.R. and found 216 cases (33.9%) of specific parvovirus B19 antibodies (IgG) by antibody capture ELISA. The seroprevalence rose to 36.7% when the 18 parvo B19-IgM- and/or parvo B19-DNA-positive results were included. The antibody prevalence was 24.9 (27.8% resp.) in the 0-10 years group and increased continuously in the following age groups up to 61.1% (69.4% resp.) in the 51-60 years group. 50% of the newborn infants showed parvo B19-IgG-antibodies in the cord blood (of maternal origin). No sex differences in seroprevalence were observed. Parvovirus B19 is obviously very prevalent in the G.D.R. population. The main immunization occurs in the first 30-40 years of life but infection with parvo B19 at a later age is also well documented. Hence it follows that 35-45% of all G.D.R. females of reproductive age are susceptible to a parvovirus B19 infection.

Adolescent↗
PubMed1990

[Parvovirus B 19 infection and associated arthritis in children and adolescents].

The commonest clinical manifestation of an acute parvovirus B 19 infection is "infectious erythema (E.i.)". Both in connection with "E.i." and without typical skin symptoms, transient arthralgias can be observed relatively frequently. Moreover, patients suffering from juvenile chronic arthritis (jcA) have now been described, in whom the initial symptoms were closely related to an acute parvo B 19 infection. Fife of our own patients with arthropathies of different kinds and a well documented acute parvovirus B 19 infection are presented here and all the relevant contemporary scientific problems are discussed.

Adult↗
PubMed1990

[Some new treatment strategies for lung involvement in patients with mucoviscidosis].

Autogenic drainage, PEP mask breathing as well as physical exercise are now well established in the treatment of pulmonary disease in cystic fibrosis, but there are different opinions about oxygen therapy over a long period as well as corticosteroid treatment. First reports on amiloride inhalations seem to be hopeful, but there is no experience with cystic fibrosis children till now, therefore clinical use can not be recommended. Heart lung transplants are not to consider as an alternative treatment for all cystic fibrosis patients, in special cases it may be successful.

Child↗
PubMed1990

[High-grade tracheomalacia and tracheal stenosis in congenital esophageal atresia with lower esophagotracheal fistula (Type III b)].

Stenosis and malacia of the trachea wall can provoke chronic stridor and/or chronic bronchitis, but usually stenosis and malacia only exist separately. The finding of an infant born with atresia of the oesophagus and a lower tracheoesophageal fistula which was cured by surgery on the 1st day of life are discussed. During the following 8 months we observed persistent stridor, chronic cough and (4-times) relapsing episodes of respiratory insufficiency ("nearly-sudden-infant-death-syndrome"/NSIDS) due to gastrooesophageal reflux (GER with aspiration) and severe tracheomalacia combined with tracheostenosis and bacterial infections (Pseudomonas aeruginosa). The strategy of therapy for GER and for the tracheal abnormality are discussed.

Esophageal Atresia↗
PubMed1990

[A contribution to the frequency and assessment possibilities of chronic aspecific respiratory tract diseases (CARD)--an epidemiological study in the mostly agricultural district of Neubrandenburg].

A test was carried out in order to determine representative information on CNSRD prevalence in children at the age of 3 to 15 and to check possibilities of registration. A clinical examination was performed at a totality of 122,400 children of a district, a sample test of 2,927 children was carried out. 10% of the children suffer from chronic diseases of the respiratory tract. In 3 to 4% of these children it is required to apply an acute or frequent therapy. The incidence of asthma bronchiale totals 1 to 2%.

Adolescent↗
PubMed1990

The pediatric bronchopneumonologic consultation centres (dispensaries) for children and adolescents suffering from chronic nonspecific respiratory diseases (CNSRD) in the G.D.R.

A survey is given of the three-level health service for young patient with chronic nonspecific respiratory diseases (CNSRD) in the GDR. The expected prevalence of the diseases in the young population (0-18 years) is 2-3% and still higher in regions with heavy air pollution. The pediatric working group of bronchopneumonology (in the Pediatric Society of the GDR) has organized a country-wide system of pediatric bronchopneumonologic consultation centres in the form of district (2nd level) and county dispensaries (3rd level) helping the local primary care pediatricians and general practitioners (1st level) in diagnostics, therapy and surveillance of such patients. The bronchopneumonologic county centres with all modern diagnostic and therapeutic facilities have a capacity which is sufficient for our country. However the function of the primary care doctors (to spot such children and refer them to the dispensaries), that of the district dispensaries (so far only 50-65% of expected patients in control!), and the availability of lung function test equipment and special bronchoscopic aids for infants and small children (in the county centres) needs to be improved.

Adolescent↗